
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is attractive because gedatolisib has produced differentiated clinical results across PIK3CA wild-type and mutant HR+/HER2- breast cancer, including 9.3 months mPFS in wild-type and about 11.1 to 11.3 months in mutant disease, supporting a mutation-agnostic commercial strategy. Its launch fundamentals also look strong, with REVTORPYK available since September 30, 2026, 78% of the top 36 strategic accounts already ordering, 91% of U.S. commercial and Medicare lives covered, and cash of $642.7M funding operations through 2029. Additional upside comes from ongoing Phase 3 VIKTORIA-2 and Phase 1b/2 prostate programs, which broaden the addressable opportunity beyond the initial 2L breast cancer market and reinforce the platform’s pipeline-in-a-product profile.
Bears say
Celcuity is viewed negatively because gedatolisib faces a difficult path to approval and commercialization, with downside risks tied to additional indication failures, regulatory delays, and the need to raise sufficient capital for research and commercial build-out. Even if approved, adoption could be constrained by weekly IV dosing, stomatitis, and buy-and-bill friction, including temporary J-code reimbursement, formulary access, and manufacturing constraints at its sole production site, which may make the launch ramp slower than expected. The competitive backdrop is also unfavorable, as oral rivals and established standards in HR+/HER2- breast cancer and mCRPC can win on convenience or efficacy, while first-line endocrine-sensitive disease remains especially challenging given control arms with median PFS of 25-28 months.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Celcuity (CELC) Forecast
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares